Vascular Biogenics (VBLT) Getting Favorable Press Coverage, Analysis Finds
News coverage about Vascular Biogenics (NASDAQ:VBLT) has trended positive on Saturday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vascular Biogenics earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2706966686859 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Technical Review on Vascular Biogenics Ltd. (VBLT) – Wall Street Morning (wallstreetmorning.com)
- Investors should Buy on Stock: Vascular Biogenics Ltd. (VBLT) – Street Observer (press release) (streetobserver.com)
- Vascular Biogenics Ltd. (VBLT)- Stocks Shining Bright on Wall Street – NASDAQ Times (nasdaqtimes.com)
- Vascular Biogenics Ltd. (VBLT) 5.33% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM (finance.yahoo.com)
Vascular Biogenics (NASDAQ:VBLT) traded down 4.92% during trading on Friday, reaching $5.80. The company’s stock had a trading volume of 165,879 shares. The firm’s market cap is $156.65 million. Vascular Biogenics has a 52 week low of $3.90 and a 52 week high of $7.25. The stock’s 50 day moving average is $5.58 and its 200-day moving average is $5.20.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. On average, equities research analysts forecast that Vascular Biogenics will post ($0.74) earnings per share for the current fiscal year.
VBLT has been the subject of a number of research reports. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. HC Wainwright set a $11.00 target price on Vascular Biogenics and gave the company a “buy” rating in a research note on Tuesday, August 15th. Finally, ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Vascular Biogenics presently has an average rating of “Hold” and an average price target of $14.75.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.